Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TILs Combined With Third-Generation EGFR-TKI Therapy for TKI-Resistant Advanced NSCLC
NCT07498595Phase 1Not yet recruiting
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Mar 2026
- Primary completion
- Mar 2028
- Modality
- Monoclonal Antibodies, Cell Therapies
01
Overview
Phase 1, open-label, single-arm trial of GC101 TIL + pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Tianjin Medical University General Hospital. Primary endpoint: Incidence of treatment-related adverse events at 3 years. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
GC101 TIL + pembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07498595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07498595.